US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by eGenesis
eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure
September 03, 2026
From
eGenesis
Via
Business Wire
eGenesis Appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial Officer
June 22, 2026
From
eGenesis
Via
Business Wire
eGenesis to Participate at BIO International Convention 2026 Panel on the Future of Xenotransplantation
June 18, 2026
From
eGenesis
Via
Business Wire
eGenesis Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
March 24, 2026
From
eGenesis
Via
Business Wire
eGenesis to Present at 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
eGenesis
Via
Business Wire
eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access Study
September 08, 2025
From
eGenesis
Via
Business Wire
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
August 19, 2025
From
eGenesis
Via
Business Wire
eGenesis Appoints Dr. Jay Barth as Chief Medical Officer
May 06, 2025
From
eGenesis
Via
Business Wire
eGenesis and OrganOx Announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure
April 15, 2025
From
eGenesis
Via
Business Wire
eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney
February 07, 2025
From
eGenesis
Via
Business Wire
eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
September 04, 2024
From
eGenesis
Via
Business Wire
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
March 21, 2024
From
eGenesis
Via
Business Wire
eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan
February 13, 2024
From
eGenesis
Via
Business Wire
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
January 18, 2024
From
eGenesis
Via
Business Wire
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
October 26, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
October 11, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
June 13, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
June 05, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Knut Niss as Chief Technology Officer
January 24, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
January 09, 2023
From
eGenesis
Via
GlobeNewswire
Tickers
ELDN
